Clinical trials Brief November 6, 2026, 9:03 AM ET

AstraZeneca registers Phase III trial of AZD6234 in obesity and type 2 diabetes

The SELENE-Asia study plans to enroll 330 participants and begin recruiting on January 4, 2027. It will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.

Primary source

ClinicalTrials.gov registry record, November 6, 2026

A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

Read the source: A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation